Although the dramatic effect of highly active antiretroviral therapy (HAART) in reducing morbidity and mortality must not be underestimated, it is also important to consider the incidence and prevalence of HAART-related toxicities. Although several studies have investigated HAART-related toxicities, there has been great variety between them in the reported incidence and prevalence rates of these toxicities. Various factors, including whether the study type was a clinical trial or an observational study, the definition of the toxicity endpoints, the demographic characteristics of the study populations and the effect of calendar year on analyses, may all influence the rates observed. We investigated the possible explanations for the differences in the incidence and prevalence rates of HAART-related toxicities between studies, focussing on metabolic and hepatotoxic disorders.
References
1.
MocroftA., VellaS., BenfieldT.L., ChiesiA., MillerV., GargalianosP., d'Arminio MonforteA., YustI., BruunJ.N., PhillipsA.N., & LundgrenJ.N. for the EuroSIDA study group. Changing patterns of mortality across Europe in patients infected with HIV-1.Lancet1998; 352: 1725–1730.
2.
MocroftA., LedergerberB., KatlamaC., KirkK.A., ReissP., d'Arminio MonforteA., KnyszB., DietrichM., PhillipsA.N., & LundgrenJ.D.Decline in the AIDS and death rates in the EuroSIDA study: an observational study.Lancet2003; 362: 22–29.
3.
PalellaF.J., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.New England Journal of Medicine1998; 338: 853–860.
4.
PowderlyW.G.Long-term exposure to lifelong therapies.Journal of Acquired Immune Deficiency Syndromes2002; 29: S28–S40.
5.
Arenas-PintoA., GrantA.D., EdwardsS., & WellerI.V.D.Lactic acidosis in HIV infected patients: a systematic review of published cases.Sexually Transmitted Infections2003; 79: 344.
6.
MondyK., YarasheskiK., PowderlyW.G., WhyteM., ClaxtonS., DeMarcoD., HoffmannM., & TebasP.Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.Clinical Infectious Diseases2003; 36: 482–490.
7.
CarrA., & CooperD.A.Adverse effects of antiretroviral therapy.Lancet2000; 356: 1423–1430.
FagotJ.P., MockenhauptM., Bouwes-BavinckJ.N., NaldiL., ViboudC., & RoujeauJ.C.Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.AIDS2001; 15: 1848.
10.
SundarK.Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature.Critical Care Medicine1997; 8: 1425–1430.
11.
PhillipsA.N., GrabarS., TassieJ.M., CostagliolaD., LundgrenJ.N., & EggerM.Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials.AIDS1999; 13: 2075–2082.
12.
SabinC.A., & PhillipsA.N.Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies.Journal of Antimicrobial Chemotherapy2001; 47: 371–375.
13.
RhewD.C., BernalM., AguilarD., IloejeU., & GoetzM.B.Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.Clinical Infectious Diseases2003; 37: 959–972.
14.
GrahamN.M.Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.Journal of Acquired Immune Deficiency Syndromes2000; 25: S4–S11.
15.
WankeC.A.Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome.AIDS1999; 13: 1287–1293.
16.
JohnM., NolanD., & MallalS.Editorial review: antiretroviral therapy and the lipodystrophy syndrome.Antiviral Therapy2001; 6: 9–20.
MurphyR.L., & SmithW.J.Switch studies: a review.HIV Medicine2002; 3: 146–155.
19.
SafrinS., & GrunfeldC.Fat distribution and metabolic changes in patients with HIV infection.AIDS1999; 13: 2493–2505.
20.
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.Combination antiretroviral therapy and the risk of myocardial infarction.New England Journal of Medicine2003; 349: 1993–2003.
21.
KleinD., HurleyL.B., QuesenberryC.P., & SidneyS.Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?Journal of Acquired Immune Deficiency Syndromes2002; 30: 471–477.
22.
Mary-KrauseM., CotteL., SimonA., PartisaniM., & CostagliolaD.Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.AIDS2003; 17: 2479–2486.
23.
BozzetteS.A., AkeC.F., TamH.K., ChangS.W., & LouisT.A.Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.New England Journal of Medicine2003; 148: 702–710.
24.
CoplanP.M., NikasA., JapourA., CormierK., Maradit-KremersH., LewisR., XuY., & DiNubileM.J.Incidence of myocardial infarction in randomised clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.AIDS Research & Human Retroviruses2003; 19: 449–455.
Friss-MollerN., WeberR., ReissP., ThiebautR., KirkO., d'Arminio MonforteA., PradierC., MorfeldtL., MateuS., LawM., El-SadrW., De WitS., SabinC.A., PhillipsA.N., & LundgrenJ.D.Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy.AIDS2003; 17: 1179–1193.
27.
VisnegarwalaF., DarcourtJ., SajjaP., MenonV., OngO., MaldonadoM., & WhiteA.C.Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus no-protease inhibitor containing HAART regimens.Journal of Acquired Immune Deficiency Syndromes2003; 33: 653–654.
28.
KoppelK., BrattG., SchulmanS., BylundH., & SandstromE.Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.Journal of Acquired Immune Deficiency Syndromes2001; 29: 441–449.
29.
CollazosJ., MayoJ., IbarraS., & CazallasJ.Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection.AIDS2003; 17: 927–929.
30.
ThiebautR., DabisF., MalvyD., Jacqmin-GaddaH., MercieP., & DaucourtV.Serum triglycerides, HIV infection and highly active antiretroviral therapy, Acquitaine Cohort, France, 1996 to 1998.Journal of Acquired Immune Deficiency Syndromes2000; 23: 261–265.
31.
MatthewsG.V., MoyleG.J., MandaliaS., BowerM., NelsonM., & GazzardB.G.Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1 infected persons on initial therapy.Journal of Acquired Immune Deficiency Syndromes2000; 24: 310–315.
32.
van LethF., PhanuphakP., GazzardB., CahnP., WoodR., BlochM., KatlamaC., SchechterM., MurphyR., HorbanA., HallD., van der ValkM., LangeJ., & ReissP.Lipid changes in a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirinz alone or both drug combined, together with stavudine and lamivudine (2NN study).10th Conference on Retroviruses & Opportunistic Infections. 10–14 February 2003, Boston, Mass., USA. Abstract 752.
33.
PeriardD., TelentiA., SudreP., CheseauxJ.J., HalfonP., ReymondM., MarcovinaS.M., GlauserM.P., NicodP., DarioliR., & MooserV. for the Swiss HIV cohort. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors.Circulation1999; 100: 700–705.
34.
BehrensG., DejamA., SchmidtH., BalksH.J., BrabantG., KornerT., StollM., & SchmidtR.E.Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.AIDS1999; 13: F63–F70.
35.
NegredoE., RibaltaJ., ParadesR., FerreR., SireraG., RuizL., SalazarJ., ReissP., MasanaL., & ClotetB.Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.AIDS2002; 16: 1383–1389.
36.
PikettyC., PeytavinG., TrylezinskiA., Gonzalez-CanaliG., CastielP., WeissL., & KazatchineM.D.Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirinz.HIV Medicine2002; 3: 287–289.
37.
CostaA., PulidoF., RubioR., CepedaC., TorralbaM., & CostaJ.R.Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy.AIDS2002; 16: 1983–1984.
38.
LichensteinK.A., DelaneyK.M., ArmonC., WardD.J., MoormanA.C., WoodK.C., & HolmbergS.D.Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients.Journal of Acquired Immune Deficiency Syndromes2003; 32: 48–56.
39.
RakotoambininaB., MedioniJ., RabianC., JubaultV., JaisJ-P, & ViardJ. P.Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.Journal of Acquired Immune Deficiency Syndromes2001; 27: 443–449.
40.
van der ValkM., GisolfE.H., WitF.W., JapourA., WeverlingG.J., & DannerS.A.Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.AIDS2001; 15: 847–855.
41.
CarrA., SamarasK., BurtonS., LawM., FreundJ., ChisholmD.J., & CooperD.A.A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.AIDS1998; 12: F51–F58.
42.
MartinezE., ArnaizJ.A., PodzamczerD., DalmauD., RiberaE., DomingoP., KnobelH., RinaldoC., PedrolE., ForceL., LlibreJ.M., SeguraF., RichartC., CortesC., JavaloyasM., ArandaM., CrucetaA., de LazzariE., & GatellJ.Substitution of nevirapine, efavirinz, or abacavir for Protease inhibitors in patients with human immunodeficiency virus infection.New England Journal of Medicine2003; 349: 1036–1046.
43.
JolyV., FlandreP., MeiffredyV., LeturqueN., HarelM., AboulkerJ.P., & YeniP.Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.AIDS2002; 16: 2447–2454.
44.
HeathK.V., HoggR., SingerJ., ChanK.J., O'ShaughnessyM.V., & MontanerJ.S.G.Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort.Journal of Acquired Immune Deficiency Syndromes2002; 30: 440–447.
45.
HadiganC., MeigsJ.B., CorcoranC., ReitschelP., BasgozN., DavisB., SaxP., StanleyT., WilsonP.W.F., D'AgostinoR.B., & GrinspoonS.Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.Clinical Infectious Diseases2001; 32: 130–139.
46.
CarrA., SamarasK., ThorisdottirA., KaufmannG.R., ChisholmD.J., & CooperD.A.Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus.Lancet1999; 353: 2093–2099.
47.
TsiodrasS., MantzorosC., HammerS., & SamoreM.Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy.Archives of Internal Medicine2000; 160: 2050–2056.
RuizL., NegredoE., DomingoP., ParadesR., FranciaE., BalagueM., GelS., BonjochA., FumazC.R., JohnstonS., RomeuJ., LangeJ.M.A., & ClotetB.Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomised, controlled study.Journal of Acquired Immune Deficiency Syndromes2001; 27: 229–236.
50.
MatheronS., DescampsD., BoueF., LivrozetJ.M., LafeuilladeA., AquilinaC., TroisvalletsD., GoetschelA., Brun-VezinetF., MametJ.P., & ThiauxC.; C.N.A.3007 Study Group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.Antiviral Therapy2003; 8: 163–171.
51.
HeathK.V., ChanK.J., SingerJ., O'ShaughnessyM.V., MontanerJ.S.G., & HoggR.S.Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.International Journal of Epidemiology2002; 31: 1016–1020.
52.
MartinezE., CongetI., LozanoL., CasamitjanaR., & GatellJ.Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.AIDS1999; 13: 805–810.
53.
GrunfeldC., PangM., DoerrlerW., ShigenagaJ.K., JensenP., & FeingoldK.R.Lipids, lipoproteins, triglyceride clearence and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.Journal of Clinical Endocrinology & Metabolism1992; 74: 1045–1052.
54.
BehrensG.M., Meyer-OlsonD., StollM., & SchmidtR.E.Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease.AIDS2003; 17: S149–S154.
55.
GrunfeldC., KotlerD.P., HamadehR., TierneyA., WangJ., & PiersonR.N.Hypertriglyceridaemia in the acquired immunodeficiency syndrome.American Journal of Medicine1989; 86: 27–31.
56.
Rodriguez-GuardadoA., MaradonaJ.A., CartonJ.A., & AsensiV.Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy.AIDS2003; 16: 1434–1436.
57.
StoneS.F., LeeS., KeaneN.M., PriceP., & FrenchM.A.Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.Journal of Infectious Diseases2002; 186: 1498–1502.
58.
De SimoneJ.A., PomerantzR.J., & BabinchakT.J.Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.Annals of Internal Medicine2000; 133: 447–454.
59.
PomerantzR.J.The expert speaks: immune reconstitution in AIDS.AIDS Patient Care & STDs2003; 17: 99–101.
60.
SavesM., VandentorrenS., DaucourtV., MarimoutouC., DuponM., CouzigouP., BernardN., MercieP., & DabisF.Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996–1998.AIDS1999; 13: 115–151.
61.
GisolfE.H., DreezenC., DannerS.A., WeelJ., & WeverlingG.J.Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine.Clinical Infectious Diseases2000; 31: 1234–1239.
62.
d'Arminio MonforteA., BugariniR., PezzottiP., de LucaA., AntinoriA., MussiniC., VigevaniM., TirelliU., BrunoR., GrittiF., PiazzaM., ChigiottiS., ChirianniA., De StefanoC., PizzigalloE., PerrellaO., & MoroniM. for the ICONA study group. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.Journal of Acquired Immune Deficiency Syndromes2001; 28: 114–123.
63.
AcetiA., PasquazziC., ZechiniB., & De BacC.Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV.Journal of Acquired Immune Deficiency Syndromes2002; 29: 41–48.
64.
NunezM., LanaR., MendozaJ.L., Martin-CarboneroL., & SorianoV.Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.Journal of Acquired Immune Deficiency Syndromes2001; 27: 426–431.
65.
BonfantiP., LandonioS., RicciE., MartinelliC., FortunaP., FaggionI., & QuirinoT.Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy.Journal of Acquired Immune Deficiency Syndromes2001; 27: 316–318.
66.
SulkowskiM.S., ThomasD.L., ChaissonR.E., & MooreR.D.Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.Journal of the American Medical Association2000; 283: 74–80.
67.
den BrinkerM., WitF.W.N.M., Wertheim-van DillenP.M.E., JurriaansS., WeelJ., van LeeuwenD.M., PakkerN.G., ReissP., DannerS.A., WeverlingG.J., & LangeJ.M.A.Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.AIDS2000; 14: 2895–2902.
SavesM., RaffiF., ClevenberghP., MarchouB., Walder-CombernouxA., MorlatP., Le MoingV., RiviereC., CheneG., & LeportC. for the APROCO Study Group. Hepatitis B or Hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients.Antimicrobial Agents & Chemotherapy2000; 44: 3451–3455.
70.
WitF.W.N.M., WeverlingG.J., WeelJ., JurriaansS., & LangeJ.M.A.Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.Journal of Infectious Diseases2002; 186: 22–31.
71.
SulkowskiM.S., ThomasD.L., MehtaS.H., ChaissonR.E., & MooreR.D.Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Hepatology2002; 35: 182–189.
72.
PalmonR., KooB.C.A., ShoultzD.A., & DieterichD.T.Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.Journal of Acquired Immune Deficiency Syndromes2002; 29: 340–345.
ConcatoJ., ShahN., & HorwitzR.I.Randomized, controlled trials, observational studies, and the hierarchy of research designs.New England Journal of Medicine2000; 342: 1887–1892.
75.
SabinC.A.The role of observational studies in assessing the impact of antiviral therapies.Current Opinion in Infectious Diseases2000; 13: 631–635.
76.
DunnD., BabikerA.G., HookerM., & DarbyshireJ.H.The dangers of inferring treatment effects from observational data: a case study in HIV infection.Controlled Clinical Trials2002; 23: 106–110.
77.
WalmsleyS., BernsteinB., KingM., ArribasJ., BeallG., RuaneP., JohnsonM., JohnsonD., LalondeR., JapourA., BrunS., & SunE.Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.New England Journal of Medicine2002; 346: 2039–2046.
78.
StaszewskiS., KeiserP., MontanerJ., RaffiF., GatheJ., BrotasV., HicksC., HammerS.M., CooperD., JohnsonM., TortellS., CutrellA., ThorbornD., IssacsR., HetheringtonS., SteelH., & SpreenW.Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral naive HIV-infected patients: a randomised equivalence trial.Journal of the American Medical Association2001; 285: 1155–1163.
79.
UngsedhapandC., KroonE.D.M.B., SuwanagoolS., RuxrungthamK., YimsuanN., SonjaiA., UbolyamS., BuranapraditkunS., TiengrimS., PakkerN.G., KunanusontC., LangeJ.M.A., CooperD.A., & PanuphakP.A randomised, open-label, comparative trial of zidovudine plus lamivudine vs zidovudine plus lamivudine plus didanosine in antiretroviral naive HIV-1-infected Thai patients.Journal of Acquired Immune Deficiency Syndromes2001; 27: 116–123.
80.
MooreD.A., GoodallR.L., IvesN.J., HookerM., GazzardB.G., & EasterbrookP.J.How generalizable are the results of large randomized controlled trials of antiretroviral therapy?HIV Medicine2000; 1: 149–154.
81.
HankinsC., LapointeN., & WalmsleyS.Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group.Canadian Medical Association Journal1998; 159: 1359–1354.
82.
MadgeS., MocroftA., WilsonD., YouleM., PhillipsA.N., TyrerM., Cozzi-LepriA., SwadenL., & JohnsonM.Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years.HIV Medicine2000; 1: 212–218.
83.
GiffordA.L., CunninghamW.E., HeslinK.C., AndersenR.M., NakazonoT., LieuD.K., ShapiroM.F., & BozzetteS.A.Participation in research and access to experimental treatments by HIV-infected patients.New England Journal of Medicine2002; 346: 1373–1382.
84.
LedermanM.M., ConnickE., LandayA., KuritzkesD.R., SpritzlerJ., St ClairM., KotzinB.L., FoxL., ChiozziM.H., LeonardJ.M., RousseauF., WadeM., D'Arc RoeJ., MartinezA., & KesslerH.Immunological responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.Journal of Infectious Diseases1998; 178: 70–79.
85.
ArnaizJ.A., MallolasJ., PodzamczerD., GerstoftJ., LundgrenJ.D., CahnP., FatkenheuerG., d'Arminio MonforteA., CasiroA., ReissP., BurgerD.M., StekM., & GatellJ.Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.AIDS2003; 17: 831–840.
86.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.MMWR Morbidity & Mortality Weekly Report1998; 47: 1–39.
87.
DielemanJ.P., van RossumA.M.C., StrickerB.C.H., SturkenboomM.C.J.M., de GrootR., TelgtD., BlokW.L., BurgerD.M., BlijenbergB.G., ZietseR., & GyssensI.C.Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.Journal of Acquired Immune Deficiency Syndromes2003; 32: 135–142.
88.
GallantJ.E.Similar 96-week renal safety profile of tenofovir DF versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirinz in antiretroviral naive patients.43rd Interscience Conference on Antimicrobial Agents & Chemotherapy, 14–17 September 2003, Chicago, Ill., USA. Abstract H-840.
89.
CarterV.M., HoyJ. F., BaileyM., ColmanP.G., MyulasiI., & MijchA.M.The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition.HIV Medicine2001; 2: 174–180.
90.
BennP., RuffC., SauretV., CopasA., LinneyA., SmithC., & EdwardsS.G.Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans?HIV Medicine2003; 4: 325–331.
91.
CarrA., EmeryS., LawM., PulsR., LundgrenJ.D., & PowderlyW.G.; H.I.V. Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.Lancet2003; 361: 726–735.
92.
KeysA.B.Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease.1980; Cambridge, Mass., USA: Harvard University Press.
93.
CoreshJ., TotoR.D., KirkK.A., WheltonP.K., MassryS., JonesC., AgodoaL., & Van LenteF.Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study.American Journal of Kidney Disease1998; 32: 32–42.
94.
TotoR.D., KirkK.A., CoreshJ., JonesC., AppelL., WrightJ., CampeseV., OlutadeB., & AgodoaL.Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study.Journal of the American Society of Nephrology1997; 8: 279–287.
95.
AIDS Clinical Trials Group. Table of Grading and Severity of Adult Adverse Experiences.1996; Rockville, USA: Division of AIDS; National Institute of Allergy and Infectious Diseases.
96.
EberlyL.E., StamlerJ., & NeatonJ.D.Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease.Archives of Internal Medicine2003; 163: 1077–1083.
97.
SmithC.J., LevyI., SabinC.A., KayaE., JohnsonM.A., & LipmanM.C.I.Cardiovascular disease risk factors and anti-retroviral therapy in an HIV-positive UK population.HIV Medicine2004; 5: 88–92.
98.
HodgsonC., HodgsonL., MuradS., HermanJ., TaylorC., MacallanD., & EasterbrookP.J.Prevalence of cardiovascular disease (CVD) risk factors in an ethnically diverse HIV-positive population.8th Annual Conference of the British HIV Association (BHIVA). 18–21 April 2002, York, UK. Abstract P2.
99.
KhotU.N., KhotM.B., BajzerC.T., SappS.K., OhmanE.M., EllisS.G., LincoffA.M., & TopolE.J.Prevalence of conventional risk factors in patients with coronary heart disease.Journal of the American Medical Association2003; 290: 904.
100.
SavesM., CheneG., DucimetiereP., LeportC., Le MoalG., AmouyelP., ArveilerD., RuidavetsJ.B., ReynesJ., BinghamA., & RaffiF.Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.Clinical Infectious Diseases2003; 37: 292–298.
101.
PirisiM., ToniuttoP., FabrisC., FalletiE., TisminetzkyS.G., BaralleF., & BartoliE.Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug users.Journal of Clinical Epidemiology1998; 51: 423–427.
102.
BarrettS., KieranN., RyanE., O'KeaneJ.C., & CroweJ.Intrahepatic hepatitis C viral RNA status of serum polymerase chain reaction-negative individuals with histological changes on liver biopsy.Hepatology2001; 33: 1496–1502.
